Anteris DurAVR THV shows promise in severe aortic stenosis patients with small annuli.

Anteris Technologies has released 30-day clinical outcomes for its DurAVR THV in severe aortic stenosis patients with small aortic annuli. The DurAVR THV demonstrated single-digit mean gradients, large effective orifice areas, and no moderate or severe paravalvular leaks. The late-breaking science was presented at PCR London Valves conference with simultaneous publication online in EuroIntervention.